At FLASH Tissue Diagnostics, we are committed to transforming cancer diagnosis with our state-of-the-art technology.
Our innovative approach provides a comprehensive and cost-effective solution for lymph node analysis, ensuring no metastatic cells are missed.
By offering a more accurate and affordable diagnostic solution, we empower healthcare professionals to make more precise and quantitative analysis, enabling better patient staging and treatment.
The Current Diagnostic Dilemma
Outdated Methods, Inaccurate Results
Incomplete Metastasis Analysis
The current methods for diagnosing lymph node metastasis have remained unchanged since 1932.
These methods analyze only 0.1% of the lymph node volume, leaving a significant portion unexamined and increasing the risk of underdiagnosis.
Unable to Break the Cost Barrier
Comprehensive analysis of lymph nodes using traditional methods costs over 2000€ per lymph node.
This prohibitive cost prevents widespread clinical adoption and limits access to accurate diagnosis for many patients.
Inaccurate Diagnoses Risk Lives
Studies have shown that up to 40% of cancer patients are underdiagnosed due to the limitations of current diagnostic techniques (Burg et al., 2021).
This underdiagnosis leads to improper treatment plans, adversely affecting patient survival rates and quality of life.
The Challenge of Accurate Cancer Diagnosis
A large percentage of lymph node metastases are underdiagnosed due to inaccurate methods.
The Unique Advantages of FLASH Technology
Comprehensive, Cost-Effective and Accurate: Why FLASH Outperforms Traditional Methods
01
Comprehensive Analysis
Ensuring No Metastatic Cells Are Missed
FLASH technology screens the entire lymph node, providing a thorough and quantitative analysis. This comprehensive approach ensures that no metastatic cells are missed, leading to more accurate staging and treatment decisions.
02
Time & Cost-Effective
Affordable Diagnosis for Widespread Clinical Adoption
FLASH technology significantly shortens the time needed for comprehensive tissue analysis, resulting in lower costs.
03
Improved Outcomes
Enhancing Patient Survival Rates with Accurate Staging
Enhanced detection of lymph node metastasis can save 10% of cancer patients by ensuring accurate staging and treatment.
04
Clinical Compatibility
Seamless Clinical Integration: FLASH Complements Standard Histopathology
FLASH analysis is fully compatible with standard histopathology, allowing seamless integration into clinical practice.
05
Versatility
A Versatile Diagnostic Tool: Optimized for Lymph Nodes and Beyond
While optimized for lymph nodes, FLASH can be adapted for other diagnostic processes, including melanoma and ovarian cancer.
Unmatched Precision at a Fraction of the Cost
Life-saving for patients
Early and accurate detection of cancer metastasis can improve patient outcomes.
Cost-saving for payors
FLASH Diagnostics improves clinical decision making and optimises use of healthcare resources.
Time-saving for pathologists
FLASH Diagnostics screens the entire lymph node to reduce misdiagnosis.
Saving lives through precision. FLASH Tissue Diagnostics makes every result count—at a reduced cost.
Our Expert Team and Esteemed Partners
Axel Behrens, PhD
Chief Scientific Officer (CSO)
Axel is a world-leading cancer researcher, director of the Cancer Research UK Convergence Science Centre, and a professor at both the Institute of Cancer Research and Imperial College London, with numerous prestigious accolades and memberships in Academia Europaea and EMBO.
Hendrik Messal, PhD
Chief Technology Officer (CTO)
Hendrik, first author of the groundbreaking Nature publication on FLASH technology and recipient of the 2022 Early Career Research Award by the Biochemical Society, is a leading cancer biologist known for his contributions to 3D whole organ imaging, cancer architecture, and 3D histopathology.
Karim Tabiti, PhD
Chief Executive Officer (CEO)
Karim is an experienced executive, having served as CEO of Biotype GmbH, led reagent and system business at Immunodiagnostic Systems, and held senior roles at Roche Diagnostics, specializing in product strategy, marketing, and commercialization.
Christine Munz, PhD
Advisory Board
Christine is a seasoned executive with 20+ years in life sciences and diagnostics, currently CEO at Eppendorf and formerly Vice President at Leica Biosystems, specializing in strategic growth and global operations.
Kurt Zatloukal, M.D.
Advisory Board
Kurt is a former Professor of Pathology at the Medical University of Graz and CEO of Zatloukal Innovations GmbH, is an expert in molecular pathology, biobanking, and biosafety, with over 284 publications and involvement in EU research programs and international standards.
